Questions discussed in this category
The current NCCN guideline version 2.2021 is a little confusing. On page HODG-2, the clinical staging/risk classification did not include ESR, b...
Have the RAPID or CALGB 5064 studies changed your treatment approach?
NCCN recommends either ISRT with rituximab/chemotherapy or ISRT alone in this scenario. What factors help your decision making?
There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.
Would you still proceed to high-dose therapy and autologous SCT?
Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...
Although not approved, for example, are you every using AVD-nivolumab?
Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?
93219290892370327158689365546004586240404135
Papers discussed in this category
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10
Int. J. Radiat. Oncol. Biol. Phys., 2012 Jun 05
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-10
Chest, 1997-03
J. Clin. Oncol.,
Clin Genitourin Cancer, 2017 Sep 04
Eur. Urol., 2020 Jan 01
Blood, 2019-05-16
Blood,
N. Engl. J. Med., 2015-04-23
J. Clin. Oncol., 2019 Sep 10
J Clin Oncol, 2017 Mar 14
Pediatric blood & cancer, 2017-04
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20
J Clin Oncol, 2020 Apr 28
Blood, 2009-09-03